Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua A Ray

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Swiss Medical Weekly|June 17, 2006
Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in SwitzerlandAndrew J Palmer, Stéphane Roze, William J Valentine, et al.
Advances in Therapy|June 6, 2006
Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPHWilliam J Valentine, Andrew J Palmer, Katrina M Erny-Albrecht, et al.
Current Medical Research and Opinion|March 16, 2007
Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomesJoshua A Ray, Kristina S Boye, Nicole Yurgin, et al.
Health Services Research|September 14, 2007
Cost-effectiveness of diabetes case management for low-income populationsTodd P Gilmer, Stéphane Roze, William J Valentine, et al.
Current Medical Research and Opinion|November 2, 2006
A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertensionAndrew J Palmer, William J Valentine, Daniel M D Tucker, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Swiss Medical Weekly|June 17, 2006
Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in SwitzerlandAndrew J Palmer, Stéphane Roze, William J Valentine, et al.
Advances in Therapy|June 6, 2006
Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPHWilliam J Valentine, Andrew J Palmer, Katrina M Erny-Albrecht, et al.
Current Medical Research and Opinion|March 16, 2007
Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomesJoshua A Ray, Kristina S Boye, Nicole Yurgin, et al.
Health Services Research|September 14, 2007
Cost-effectiveness of diabetes case management for low-income populationsTodd P Gilmer, Stéphane Roze, William J Valentine, et al.
Current Medical Research and Opinion|November 2, 2006
A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertensionAndrew J Palmer, William J Valentine, Daniel M D Tucker, et al.
Pageof 2